Judith V M G BovÃ©e

List of Publications by Year
in descending order

238	12,517	17440 63	34986 98
papers	citations	h-index	g-index

241	241	241	11708
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Clinical Approach Towards Chondrosarcoma. Oncologist, 2008, 13, 320-329.	3.7	602
2	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics, 2011, 43, 1256-1261.	21.4	488
3	Soft tissue and visceral sarcomas: ESMOâ€"EURACANâ€"GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ˜†. Annals of Oncology, 2021, 32, 1348-1365.	1.2	381
4	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2â€"3, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1148-1159.	10.7	288
5	Identification of a novel, recurrent HEY1â€NCOA2 fusion in mesenchymal chondrosarcoma based on a genomeâ€wide screen of exonâ€level expression data. Genes Chromosomes and Cancer, 2012, 51, 127-139.	2.8	276
6	Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nature Reviews Cancer, 2010, 10, 481-488.	28.4	236
7	Multiple osteochondromas. Orphanet Journal of Rare Diseases, 2008, 3, 3.	2.7	234
8	Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors. American Journal of Surgical Pathology, 2009, 33, 50-57.	3.7	216
9	The Clinical Approach Toward Giant Cell Tumor of Bone. Oncologist, 2014, 19, 550-561.	3.7	199
10	Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Research Notes, 2011, 4, 1.	1.4	177
11	EXT-Mutation Analysis and Loss of Heterozygosity in Sporadic and Hereditary Osteochondromas and Secondary Chondrosarcomas. American Journal of Human Genetics, 1999, 65, 689-698.	6.2	174
12	Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. American Journal of Surgical Pathology, 2015, 39, 1576-1583.	3.7	174
13	Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncology, The, 2005, 6, 599-607.	10.7	171
14	Incidence, Predictive Factors, and Prognosis of Chondrosarcoma in Patients with Ollier Disease and Maffucci Syndrome: An International Multicenter Study of 161 Patients. Oncologist, 2011, 16, 1771-1779.	3.7	169
15	MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosis. Genes Chromosomes and Cancer, 2015, 54, 361-368.	2.8	167
16	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Modern Pathology, 2016, 29, 582-590.	5.5	164
17	Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood, 2014, 123, 3152-3155.	1.4	161
18	Linkage-Specific in Situ Sialic Acid Derivatization for N-Glycan Mass Spectrometry Imaging of Formalin-Fixed Paraffin-Embedded Tissues. Analytical Chemistry, 2016, 88, 5904-5913.	6.5	158

#	Article	IF	Citations
19	The CpG Island Methylator Phenotype: What's in a Name?. Cancer Research, 2013, 73, 5858-5868.	0.9	154
20	Genes Involved in the Osteoarthritis Process Identified through Genome Wide Expression Analysis in Articular Cartilage; the RAAK Study. PLoS ONE, 2014, 9, e103056.	2.5	142
21	Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma. Laboratory Investigation, 2000, 80, 1925-1934.	3.7	130
22	Chondrosarcoma of the phalanx. Cancer, 1999, 86, 1724-1732.	4.1	129
23	Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. , 1999, 189, 454-462.		111
24	Enchondromatosis: insights on the different subtypes. International Journal of Clinical and Experimental Pathology, 2010, 3, 557-69.	0.5	106
25	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Annals of Oncology, 2020, 31, 1506-1517.	1.2	103
26	Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment. Cancer Research, 2009, 69, 6216-6222.	0.9	102
27	The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions. Journal of the National Cancer Institute, 2007, 99, 396-406.	6.3	101
28	Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Annals of Oncology, 2012, 23, 1617-1626.	1.2	101
29	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancerâ€“Soft Tissue and Bone Sarcoma Group (EORTCâ€“STBSG) recommendations for pathological examination and reporting. European Journal of Cancer, 2016, 53, 84-95.	2.8	99
30	Current State and Future Challenges of Mass Spectrometry Imaging for Clinical Research. Analytical Chemistry, 2015, 87, 6426-6433.	6.5	98
31	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 2021, 127, 2934-2942.	4.1	96
32	Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes and Cancer, 2012, 51, 899-909.	2.8	95
33	Molecular pathology of sarcomas: concepts and clinical implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 193-199.	2.8	93
34	Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. , 1999, 26, 237-246.		92
35	Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget, 2015, 6, 38777-38788.	1.8	90
36	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 119-128.	4.2	89

#	Article	IF	Citations
37	Higher incidence rates than previously known in tenosynovial giant cell tumors. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 688-694.	3.3	87
38	Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. Journal of Pathology, 2005, 205, 476-482.	4.5	86
39	Multimodal Mass Spectrometry Imaging of N-Glycans and Proteins from the Same Tissue Section. Analytical Chemistry, 2016, 88, 7745-7753.	6.5	86
40	Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCRâ€“Based Targeted Next-Generation Sequencing. Journal of Molecular Diagnostics, 2018, 20, 653-663.	2.8	85
41	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Modern Pathology, 2016, 29, 1028-1037.	5.5	84
42	Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 downâ€regulation and p16 overexpression inhibit cell growth in vitro. Journal of Cellular and Molecular Medicine, 2009, 13, 2843-2852.	3.6	83
43	Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer, 2014, 120, 3159-3164.	4.1	83
44	Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Modern Pathology, 2012, 25, 212-221.	5.5	81
45	Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget, 2015, 6, 12505-12519.	1.8	81
46	Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional(central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. Journal of Pathology, 2004, 202, 359-366.	4.5	80
47	Molecular pathology and its diagnostic use in bone tumors. Cancer Genetics, 2012, 205, 193-204.	0.4	80
48	A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Modern Pathology, 2020, 33, 404-419.	5.5	80
49	Diagnosis and prognosis of chondrosarcoma of bone. Expert Review of Molecular Diagnostics, 2002, 2, 461-472.	3.1	79
50	USP6 activation in nodular fasciitis by promoter-swapping gene fusions. Modern Pathology, 2017, 30, 1577-1588.	5.5	79
51	Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy. Clinical Cancer Research, 2013, 19, 3796-3807.	7.0	77
52	GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma. Nature Genetics, 2014, 46, 474-477.	21.4	75
53	Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas. PLoS Computational Biology, 2019, 15, e1006826.	3.2	75
54	Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. Laboratory Investigation, 2010, 90, 1091-1101.	3.7	73

#	Article	IF	Citations
55	Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors. Advances in Anatomic Pathology, 2013, 20, 32-38.	4.3	73
56	FUS rearrangements are rare in â€˜pure' sclerosing epithelioid fibrosarcoma. Modern Pathology, 2012, 25, 846-853.	5.5	72
57	IWR-1, a tankyrase inhibitor, attenuates Wnt/Î²-catenin signaling in cancer stem-like cells and inhibits inÂvivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Letters, 2018, 414, 1-15.	7.2	72
58	Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors. Clinical Cancer Research, 2009, 15, 2685-2694.	7.0	71
59	Multiple Osteochondromas: Clinicopathological and Genetic Spectrum and Suggestions for Clinical Management. Hereditary Cancer in Clinical Practice, 2004, 2, 161.	1.5	69
60	Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes and Cancer, 2015, 54, 565-574.	2.8	69
61	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients withIDH1-mutated orIDH2-mutated solid tumours. BMJ Open, 2017, 7, e014961.	1.9	69
62	Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Human Mutation, 2004, 24, 466-473.	2.5	68
63	No Haploinsufficiency but Loss of Heterozygosity for EXT in Multiple Osteochondromas. American Journal of Pathology, 2010, 177, 1946-1957.	3.8	67
64	Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. Journal of Pathology, 2006, 209, 501-511.	4.5	66
65	Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma. Hematology/Oncology Clinics of North America, 2013, 27, 1021-1048.	2.2	65
66	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open, 2021, 6, 100170.	4.5	65
67	NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Modern Pathology, 2015, 28, 587-595.	5.5	64
68	Osteosarcoma Stem Cells Have Active Wnt/Î²â€catenin and Overexpress SOX2 and KLF4. Journal of Cellular Physiology, 2016, 231, 876-886.	4.1	62
69	R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations. American Journal of Pathology, 2013, 182, 1494-1500.	3.8	60
70	Near-Haploidy and Subsequent Polyploidization Characterize the Progression of Peripheral Chondrosarcoma. American Journal of Pathology, 2000, 157, 1587-1595.	3.8	59
71	Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. Journal of Pathology, 2007, 211, 399-409.	4.5	57
72	Distinct histological features characterize primary angiosarcoma of bone. Histopathology, 2011, 58, 254-264.	2.9	57

#	Article	IF	Citations
73	Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. , 1998, 184, 24-30.		53
74	Malignant progression in multiple enchondromatosis (Ollier's disease): An autopsy-based molecular genetic study. Human Pathology, 2000, 31, 1299-1303.	2.0	53
75	Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma. Clinical Cancer Research, 2005, 11, 8028-8035.	7.0	53
76	Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFÎ² as Potential Targets. American Journal of Pathology, 2013, 182, 1347-1356.	3.8	53
77	Prevalence of cartilaginous tumours as an incidental finding on MRI of the knee. European Radiology, 2015, 25, 3480-3487.	4.5	53
78	Array-comparative genomic hybridization of central chondrosarcoma. Cancer, 2006, 107, 380-388.	4.1	51
79	Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. Human Pathology, 2013, 44, 1597-1604.	2.0	51
80	cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade. Journal of Pathology, 2005, 207, 61-71.	4.5	50
81	A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. Journal of Pathology, 2008, 216, 158-166.	4.5	50
82	Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients. Human Mutation, 2011, 32, E2036-E2049.	2.5	50
83	IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. Clinical Sarcoma Research, 2017, 7, 8.	2.3	50
84	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head and Neck, 2017, 39, 140-146.	2.0	48
85	Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology, 2010, 56, 641-651.	2.9	46
86	Expression of cartilage growth plate signalling molecules in chondroblastoma. Journal of Pathology, 2004, 202, 113-120.	4.5	45
87	Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. Oncogenesis, 2018, 7, 74.	4.9	45
88	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. JAMA Oncology, 2021, 7, e205865.	7.1	45
89	Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 455-463.	2.8	44
90	Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Current Opinion in Oncology, 2016, 28, 314-322.	2.4	43

#	Article	IF	Citations
91	Aberrant Heparan Sulfate Proteoglycan Localization, Despite Normal Exostosin, in Central Chondrosarcoma. American Journal of Pathology, 2009, 174, 979-988.	3.8	42
92	Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surgical Pathology Clinics, 2016, 9, 457-473.	1.7	42
93	COX-2 expression in chondrosarcoma: A role for celecoxib treatment?. European Journal of Cancer, 2010, 46, 616-624.	2.8	40
94	Chromosome 9 Alterations and Trisomy 22 in Central Chondrosarcoma: A Cytogenetic and DNA Flow Cytometric Analysis of Chondrosarcoma Subtypes. Diagnostic Molecular Pathology, 2001, 10, 228-235.	2.1	40
95	Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia. Journal of Bone and Mineral Research, 2018, 33, 84-90.	2.8	39
96	Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. Monthly Notices of the Royal Astronomical Society: Letters, 2018, 89, 570-574.	3.3	39
97	Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin. Oncotarget, 2015, 6, 36113-36125.	1.8	39
98	The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 430-437.	2.8	38
99	BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors. BMC Cancer, 2012, 12, 488.	2.6	38
100	Avenâ€mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. Journal of Pathology, 2015, 236, 348-359.	4.5	38
101	Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. European Journal of Cancer, 2016, 53, 171-180.	2.8	38
102	Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Modern Pathology, 2012, 25, 1275-1283.	5.5	37
103	Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging. Journal of the American Society for Mass Spectrometry, 2017, 28, 376-383.	2.8	37
104	Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. British Journal of Cancer, 2018, 118, 1074-1083.	6.4	37
105	Genome-wide analysis of Ollier disease: Is it all in the genes?. Orphanet Journal of Rare Diseases, 2011, 6, 2.	2.7	36
106	Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. BMC Cancer, 2012, 12, 375.	2.6	36
107	NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma. Molecular Cancer Research, 2017, 15, 1714-1721.	3.4	36
108	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. OncoImmunology, 2018, 7, e1386828.	4.6	36

#	Article	IF	Citations
109	Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. Journal of Biological Chemistry, 2017, 292, 21282-21290.	3.4	35
110	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. Clinical Cancer Research, 2018, 24, 2678-2687.	7.0	35
111	EXT-related pathways are not involved in the pathogenesis of dysplasia epiphysealis hemimelica and metachondromatosis. Journal of Pathology, 2006, 209, 411-419.	4.5	34
112	Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency. Journal of Pathology, 2015, 236, 210-218.	4.5	34
113	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist, 2019, 24, 110-116.	3.7	34
114	Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. Clinical Sarcoma Research, 2019, 9, 9.	2.3	34
115	Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. Clinical Sarcoma Research, 2014, 4, 11.	2.3	33
116	Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes and Cancer, 2017, 56, 750-757.	2.8	33
117	Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature. Skeletal Radiology, 2019, 48, 1059-1067.	2.0	33
118	Whatâ€™s new in bone forming tumours of the skeleton?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 147-157.	2.8	33
119	The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. Oncotarget, 2015, 6, 14832-14842.	1.8	33
120	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
121	Primary vascular tumors of bone: a spectrum of entities?. International Journal of Clinical and Experimental Pathology, 2011, 4, 541-51.	0.5	32
122	Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes. Modern Pathology, 2009, 22, 1489-1498.	5.5	31
123	Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 475-481.	2.8	31
124	Highâ€grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging. Proteomics, 2016, 16, 1802-1813.	2.2	31
125	Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. Laboratory Investigation, 2016, 96, 1128-1137.	3.7	31
126	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. Laboratory Investigation, 2018, 98, 41-50.	3.7	30

#	Article	IF	Citations
127	Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clinical Sarcoma Research, 2011, 1, 5.	2.3	29
128	Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype. Histopathology, 2015, 67, 483-490.	2.9	29
129	Histology-Guided High-Resolution Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging. Analytical Chemistry, 2015, 87, 11978-11983.	6.5	29
130	Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors. Surgical Pathology Clinics, 2017, 10, 537-552.	1.7	29
131	Nonâ€ossifying fibroma: A RASâ€MAPK driven benign bone neoplasm. Journal of Pathology, 2019, 248, 127-130.	4.5	29
132	PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. OncoImmunology, 2018, 7, e1507600.	4.6	28
133	Does <scp>CSF</scp>1 overexpression or rearrangement influenceÂbiological behaviour in tenosynovial giant cellÂtumours of the knee?. Histopathology, 2019, 74, 332-340.	2.9	28
134	YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. Modern Pathology, 2021, 34, 2211-2221.	5.5	28
135	MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. Genes and Cancer, 2015, 6, 503-512.	1.9	28
136	Chondromyxoid fibroma resemblesin vitro chondrogenesis, but differs in expression of signalling molecules. Journal of Pathology, 2005, 206, 135-142.	4.5	27
137	Array CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone. Genes Chromosomes and Cancer, 2015, 54, 72-81.	2.8	27
138	Active TGF-Î² signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart. Modern Pathology, 2013, 26, 1211-1221.	5.5	26
139	Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics. Hypoxia (Auckland, N Z), 2017, Volume 5, 11-20.	1.9	26
140	The role of noncartilage-specific molecules in differentiation of cartilaginous tumors. Cancer, 2007, 110, 385-394.	4.1	25
141	EXTra hit for mouse osteochondroma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1813-1814.	7.1	25
142	Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option. Molecular Cancer, 2010, 9, 257.	19.2	25
143	Vascular Tumors of Bone. Surgical Pathology Clinics, 2017, 10, 621-635.	1.7	25
144	Vascular tumors of bone: Imaging findings. European Journal of Radiology, 2011, 77, 13-18.	2.6	24

#	Article	IF	Citations
145	Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status. Cancers, 2019, 11, 1918.	3.7	24
146	Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors. American Journal of Surgical Pathology, 2021, 45, 1669-1681.	3.7	24
147	Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma. PLoS ONE, 2011, 6, e24977.	2.5	24
148	Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thrombosis and Haemostasis, 2016, 115, 1025-1033.	3.4	23
149	Brain Region-Specific Dynamics of On-Tissue Protein Digestion Using MALDI Mass Spectrometry Imaging. Journal of Proteome Research, 2015, 14, 5348-5354.	3.7	22
150	The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Laboratory Investigation, 2018, 98, 414-426.	3.7	22
151	Prevalence and Clinical Features of Mazabraud Syndrome. Journal of Bone and Joint Surgery - Series A, 2019, 101, 160-168.	3.0	21
152	Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. Oncotarget, 2017, 8, 14525-14536.	1.8	21
153	Expression of the immune regulation antigen CD70 in osteosarcoma. Cancer Cell International, 2015, 15, 31.	4.1	20
154	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging. Laboratory Investigation, 2020, 100, 1252-1261.	3.7	20
155	Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma. Journal of Cellular Physiology, 2010, 225, 601-611.	4.1	19
156	Cutaneous nodular fasciitis with genetic analysis: a case series. Journal of Cutaneous Pathology, 2016, 43, 1143-1149.	1.3	19
157	Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 2020, 12, 3589.	3.7	19
158	Mismatch repair deficiency is rare in bone and soft tissue tumors. Histopathology, 2021, 79, 509-520.	2.9	18
159	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Laboratory Investigation, 2016, 96, 885-894.	3.7	17
160	Cartilage-forming tumours of bone and soft tissue and their differential diagnosis. Current Diagnostic Pathology, 2001, 7, 223-234.	0.4	16
161	Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 95-102.	2.8	16
162	Molecular Pathology of Bone Tumors. Journal of Molecular Diagnostics, 2019, 21, 171-182.	2.8	16

#	Article	IF	Citations
163	Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165962.	3.8	16
164	Chondrosarcoma is not characterized by detectable telomerase activity. Journal of Pathology, 2001, 193, 354-360.	4.5	15
165	A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. BMC Cancer, 2018, 18, 92.	2.6	15
166	Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 135-146.	2.8	15
167	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. Sarcoma, 2018, 2018, 1-8.	1.3	14
168	Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. Journal of Bone Oncology, 2019, 15, 100222.	2.4	14
169	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092â€22092 STRASS trial. Cancer, 2022, 128, 2796-2805.	4.1	14
170	<scp>DOG</scp>1 expression in giantâ€cellâ€containing bone tumours. Histopathology, 2016, 68, 942-945.	2.9	13
171	Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy. British Journal of Cancer, 2016, 114, 1219-1226.	6.4	13
172	Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis. Histopathology, 2019, 75, 843-852.	2.9	13
173	Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production. Rheumatology, 2019, 58, 1065-1074.	1.9	13
174	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers, 2021, 13, 2474.	3.7	13
175	Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. OncoTargets and Therapy, 2017, Volume 10, 2963-2970.	2.0	12
176	Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1703-1713.	3.0	12
177	FOS Rearrangement and Expression in Cementoblastoma. American Journal of Surgical Pathology, 2021, 45, 690-693.	3.7	12
178	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. Clinical Cancer Research, 2021, 27, 6737-6748.	7.0	12
179	An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 101-109.	2.8	11
180	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Translational Oncology, 2017, 10, 546-554.	3.7	11

#	Article	IF	Citations
181	Loss of <scp>NF2</scp> defines a genetic subgroup of <scp>nonâ€FOS</scp>â€rearranged osteoblastoma. Journal of Pathology: Clinical Research, 2020, 6, 231-237.	3.0	11
182	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Advances, 2021, 5, 3760-3775.	5.2	11
183	Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review. Cancers, 2021, 13, 557.	3.7	10
184	Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression. International Journal of Molecular Sciences, 2021, 22, 6273.	4.1	10
185	GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics. American Journal of Surgical Pathology, 2022, 46, 1407-1414.	3.7	10
186	Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma. Oncologist, 2020, 25, e716-e721.	3.7	8
187	Gene fusions in vascular tumors and their underlying molecular mechanisms. Expert Review of Molecular Diagnostics, 2021, 21, 897-909.	3.1	8
188	Methylation and copy number profiling: emerging tools to differentiate osteoblastoma from malignant mimics?. Modern Pathology, 2022, 35, 1204-1211.	5.5	8
189	New molecular entities of soft tissue and bone tumors. Current Opinion in Oncology, 2022, 34, 354-361.	2.4	8
190	Histological Findings in Unclassified Sudden Infant Death, Including Sudden Infant Death Syndrome. Pediatric and Developmental Pathology, 2013, 16, 168-176.	1.0	7
191	Panobinostatâ€"A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report. Pediatric Blood and Cancer, 2016, 63, 1840-1843.	1.5	7
192	No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone. BMC Cancer, 2016, 16, 475.	2.6	7
193	Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis. Clinical Sarcoma Research, 2018, 8, 16.	2.3	7
194	Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma. Frontiers in Molecular Biosciences, 2020, 7, 566291.	3.5	7
195	Personalising sarcoma care using quantitative multimodality imaging for response assessment. Clinical Radiology, 2021, 76, 313.e1-313.e13.	1.1	7
196	SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. Cancers, 2021, 13, 3823.	3.7	7
197	NTRK fusions are extremely rare in bone tumours. Histopathology, 2021, 79, 880-885.	2.9	7
198	Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express the SERPINE1-FOSB Translocation. Cell Reports Medicine, 2020, 1, 100153.	6.5	7

#	Article	IF	Citations
199	Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opinion on Therapeutic Targets, 2022, 26, 333-345.	3.4	7
200	Re. Review Article entitled ?The neoplastic pathogenesis of solitary and multiple osteochondromas?. , 2000, 190, 516-517.		6
201	Maffucci syndrome: A genomeâ€wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases. Genes Chromosomes and Cancer, 2011, 50, 673-679.	2.8	6
202	A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization. Cancer Genetics, 2015, 208, 537-544.	0.4	6
203	A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival. Journal of Bone Oncology, 2019, 19, 100268.	2.4	6
204	Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review. Frontiers in Oncology, 2020, 10, 594069.	2.8	6
205	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 459-471.	3.6	6
206	Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. Biomedicines, 2021, 9, 1048.	3.2	6
207	Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics. Cancers, 2021, 13, 1126.	3.7	5
208	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.. Journal of Clinical Oncology, 2021, 39, 11566-11566.	1.6	5
209	Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000â€“2017 Netherlands Cancer Registry Database Analysis. Sarcoma, 2021, 2021, 1-8.	1.3	5
210	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta OncolÃ³gica, 2021, 60, 1557-1564.	1.8	5
211	Therapy-Related Imaging Findings in Patients with Sarcoma. Seminars in Musculoskeletal Radiology, 2020, 24, 676-691.	0.7	5
212	A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target. Laboratory Investigation, 2022, 102, 391-400.	3.7	5
213	High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas. Clinical Sarcoma Research, 2016, 6, 17.	2.3	4
214	Successful disinfection of femoral head bone graft using high hydrostatic pressure. Cell and Tissue Banking, 2018, 19, 333-340.	1.1	4
215	Jason L. Hornick: Practical soft tissue pathology: a diagnostic approach, 2nd edition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 785-786.	2.8	4
216	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. Sarcoma, 2021, 2021, 1-12.	1.3	4

#	Article	IF	Citations
217	CORR InsightsÂ®: Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-Î² as Involved in the Pathogenesis of Osteosarcoma. Clinical Orthopaedics and Related Research, 2016, 474, 190-192.	1.5	3
218	Molecular Pathology of Bone Tumors: What Have We Learned and How Does It Affect Daily Practice?. Surgical Pathology Clinics, 2017, 10, xiii-xiv.	1.7	3
219	Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma. Diagnostics, 2021, 11, 2271.	2.6	3
220	Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 671-675.	2.8	3
221	Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes and Cancer, 1999, 26, 237-246.	2.8	2
222	Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma. Cancers, 2021, 13, 5780.	3.7	2
223	Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective. Sarcoma, 2022, 2022, 1-12.	1.3	2
224	Cartilage Tumours of Bone. , 2014, , 4079-4104.		1
225	Biology of cartilage tumor family. , 2022, , 649-662.		1
226	Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. Journal of Pathology, 1998, 184, 24-30.	4.5	1
227	The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. International Journal of Experimental Pathology, 2009, 90, 190-191.	1.3	0
228	Bone: Enchondroma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
229	Multiple osteochondromas (MO). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
230	Ollier disease. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
231	In Reply. Oncologist, 2014, 19, 1208-1208.	3.7	0
232	07.07â€…Increased expression of ccn4/wisp1 in osteoarthritic articular cartilage is epigenetically regulated and disrupts cartilage homeostasis. , 2017, , .		0
233	Molecular Drivers in Chondrosarcoma. , 2018, , 31-41.		0
234	Clinicopathological features and differential diagnosis of chondrogenic tumours. Diagnostic Histopathology, 2020, 26, 484-491.	0.4	0

#	Article	IF	Citations
235	Maffucci Syndrome. , 2008, , 353-362.		0
236	Cartilage â€“ Forming Bone Tumours. , 2011, , 23-44.		0
237	Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in the Netherlands.. Journal of Clinical Oncology, 2014, 32, 10542-10542.	1.6	0
238	Establishment of a tissue microarray (TMA) platform as an efficient tool for soft tissue sarcoma (STS) research available for collaboration.. Journal of Global Oncology, 2019, 5, 38-38.	0.5	0